SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event
reported): May 2, 2012
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified
in its charter)
(State or Other Jurisdiction
509 Madison Avenue, Suite 306, New York,
New York 10022
(Address of principal executive offices)
Registrant’s telephone number,
including area code: (212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
Harvey Kesner, Esq.
James M. Turner, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway, 32nd Floor
New York, New York 10006
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01 Regulation FD Disclosure.
The Company intends to utilize an updated
investor presentation to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the
Company intends to place on its website, which may contain non-public information. A copy of the presentation is filed
as Exhibit 99.01.
The information contained in Item 7.01
of this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to, and shall not be deemed to be "filed"
for the purposes of, Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section. The information contained in Item 7.01 of this Current Report shall not be incorporated by reference into
any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, except as otherwise
expressly stated in such filing. By filing this Current Report on Form 8-K and furnishing the information contained
in this Item 7.01, including Exhibit 99.01, the Company makes no admission as to the materiality of any such information that it
ITEM 9.01 Financial Statements and Exhibits.
||Corporate Presentation by the Company *|
* Furnished herewith.
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
||TONIX PHARMACEUTICALS HOLDING CORP.|
|Date: May 2, 2012
||By: /s/ SETH LEDERMAN|
||President and Chief Executive Officer|